The effect of nutritional supplementation on the multifocal electroretinogram in healthy eyes by Berrow, Emma J. et al.
1 
 
The effect of nutritional supplementation on the multi-focal electroretinogram in healthy eyes 1 
 2 
Emma J. Berrow 1 Hannah E. Bartlett 1 Frank Eperjesi 1 3 
 4 
1Ophthalmic Research Group, School of Life and Health Sciences, Aston University, Birmingham, 5 
United Kingdom 6 
 7 
Correspondence to Frank Eperjesi, Ophthalmic Research Group, School of Life and Health Sciences, 8 
Aston University, Aston Triangle, Birmingham, B4 7ET, United Kingdom 9 
Tel: +44 121 204 4182 10 
Email: f.eperjesi@aston.ac.uk 11 
 12 
  13 
2 
 
Abstract 1 
Background 2 
Previous studies have demonstrated an increase in macular pigment optical density (MPOD) with lutein 3 
(L)-based supplementation in healthy eyes. However not all studies have assessed whether this 4 
increase in MPOD is associated with changes to other measures of retinal function such as the 5 
multifocal ERG (mfERG). Some studies also fail to report dietary levels of L and zeaxanthin (Z). 6 
Because of the associations between increased levels of L and Z, and reduced risk for AMD, this study 7 
was designed to assess the effects of L-based supplementation on mfERG amplitudes and latencies in 8 
healthy eyes.  9 
Methods 10 
Multifocal ERG amplitudes, visual acuity (VA), contrast sensitivity (CS), MPOD and dietary levels of L 11 
and Z were assessed in this longitudinal, randomised clinical trial. Fifty two healthy eyes from 52 12 
participants were randomly allocated to receive a L-based supplement (treated group), or no 13 
supplement (non-treated group).  14 
Results 15 
There were 25 subjects aged 18-77 (mean age ± SD; 48 ± 17) in the treated group and 27 subjects 16 
aged 21-69 (mean age ± SD; 43 ± 16) in the non-treated group. All participants attended for three visits. 17 
Visit one at baseline, visit two at 20 weeks and visit three at 40 weeks. A statistically significant increase 18 
in MPOD (F 17.0, p = <0.001) and shortening of mfERG ring 2 P1 latency (F 3.69, p = 0.04) was seen 19 
in the treated group 20 
Conclusions 21 
Although the results were not clinically significant, the reported trend for improvement in MPOD and 22 
mfERG outcomes warrants further investigation.  23 
 24 
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Introduction 1 
Oxidative stress is implicated in the development of age-related macular degeneration (AMD), because 2 
of the high percentage of polyunsaturated fatty acids in the retina, which are readily oxidised [1], 3 
because of: retinal exposure to blue wavelengths of light [2], the retina is highly metabolically active [3] 4 
and phagocytosis within the retinal pigment epithelium is itself a free-radical producing process. As a 5 
result, interest has been raised in the impact of antioxidant supplementation, or dietary modification, on 6 
the onset and progression of AMD. The carotenoids lutein (L) and zeaxanthin (Z) are lipid soluble 7 
antioxidants found within the retina and together make up the macular pigment (MP). They are thought 8 
to reduce oxidative damage by filtering short wavelength blue light within the macula [4] and by 9 
quenching light-induced singlet oxygen and related free radicals [5]. Putative associations between 10 
increased levels of these carotenoids and reduced risk for development of AMD have been suggested 11 
[6-8]. Increased levels of MP optical density (MPOD) have been reported in healthy eyes and eyes with 12 
AMD when supplemented with L and Z [9-17]. Macular pigment reduces with eccentricity in the macular 13 
region [18], although is present  at much lower levels in other parts of the retina and other ocular tissues 14 
[19] 15 
 16 
Improvements in visual function in eyes with early AMD and non-exudative AMD have been reported in 17 
several studies involving carotenoids [20-23]. The Age Related Eye Disease Study 2 (AREDS2) 18 
investigators reported that substituting L and Z for beta-carotene (used in the AREDS 1 formulation) in 19 
a subset of participants resulted in the risk of progression of AMD being reduced by a further 18% over 20 
the 25 % reduction in risk already reported with the AREDS 1 formulation [24].	21 
Visual acuity (VA) is commonly used as a measure of visual function in clinical trials, but it is not an 22 
ideal outcome measure as it is subjective, assesses a relatively small retinal area, and doesn’t offer an 23 
overview of macular function. A combination of objective and subjective testing is likely to provide a 24 
more robust assessment of visual and retinal function when diagnosing AMD and assessing treatment 25 
outcomes. The multifocal electroretinogram (mfERG) can be used to objectively evaluate specific retinal 26 
areas [25]. It simultaneously assesses electrical potentials from different retinal areas [26], is valuable 27 
in the identification of focal retinal pathology and in monitoring the impact of potential treatments [27] 28 
and can be used to evaluate bipolar cell function, with some contributions from photoreceptors and 29 
retinal ganglion cells [28].  30 
The mfERG principally measures cone photoreceptor and bipolar cell function. Tubulin is found in the  31 
receptor axon layer of the cone-abundant fovea where it may selectively binds L and Z [29], leading to 32 
the MPOD increases seen on supplementation. The rationale was that an increase of L and Z binding 33 
to tubulin around the cone photoreceptor axons may have affected cone function which could be 34 
objectively assessed by the mfERG. The aim of this study was to assess the effect of a lutein (L)-based 35 
nutritional supplement on mfERG latency and amplitude in healthy eyes. Secondary outcome measures 36 
were VA, contrast sensitivity (CS) and MPOD.  37 
 38 
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Materials and methods 1 
The research was approved by Aston University Human Sciences Ethical Committee.  The tenets of 2 
the declaration of Helsinki [30] and the consolidated standards of reporting trials (CONSORT) checklist 3 
[31] were followed. The study was registered with an International Standard Randomised Controlled 4 
Trial Number (ISRCTN 17842302) and all participants provided informed written consent. 5 
The protocol used in this study has previously been reported by our research group in an investigation 6 
of the impact of L and Z supplementation on mfERG in eyes affected by age-related maculopathy [32]. 7 
We have included a description of the outcome measures here for completeness. 8 
To assess the effects of an L-based supplement in healthy eyes, 52 healthy eyes from 52 participants 9 
were randomly allocated, using the Microsoft Excel random number generator, to receive a L-based 10 
supplement (treated group) or no supplement (non-treated group) at visit 1. All participants attended for 11 
three visits. Visit one at baseline, visit two at 20 weeks and visit three at 40 weeks. All the data was 12 
collected by one of the authors (EJB) who was masked as to which participants had been allocated to 13 
the treated or non-treated group. Participants reported to another of the authors (HEB) for their 14 
randomization code and allocation of supplement tablets where appropriate. Participants were asked 15 
to contact HEB if they had any queries about supplementation. It was explained to each participant that 16 
they should not disclose whether they were in the treated or non-treated group to EJB.  17 
The supplement was Ocuvite Duo, provided by Bausch and Lomb, Kingston-Upon-Thames, Surrey, 18 
UK. The supplement had two elements. A tablet and a capsule packed in blister packs. The tablets 19 
contained all of the supplement nutrients (see table 1) except for omega 3 which was contained in the 20 
capsules. The dosage was one tablet and one capsule taken orally twice per day. All the nutrients were 21 
within the safe upper levels as defined by the UK Food Standards Agency [33]. 22 
 23 
Insert table 1 about here. 24 
 25 
Sample size 26 
Two previous studies assessing the effects of nutritional supplementation on retinal function using focal 27 
electroretinograms (fERG) [34] and mfERG [22] demonstrated significant results between groups 28 
treated with a nutritional supplement compared with non-treated groups. The fERG study suggested a 29 
sample size of 8 healthy eyes for their healthy older group and 30 eyes for the age-related maculopathy 30 
group [34], which gave a power of 90% at α = 0.05, for detecting a between group difference of 25 – 31 
30% in amplitude or phase. The mfERG study by the CARMIS investigators, had 27 ARM eyes, 15 in 32 
the supplemented group and 12 in the non-supplemented group [22] and this gave a power of 90% at 33 
α = 0.05, for detecting a between-group difference of ≥ 55% in mfERG amplitude. A 55% difference in 34 
mfERG amplitude was used as the effect size in sample size calculations for this study [22] (table 2).  35 
5 
 
Insert table 2 about here 1 
Because there is paucity in the literature about mfERG latency changes with nutritional 2 
supplementation, effect sizes for mfERG latency were based on a study of vitamin A supplementation 3 
by Dolan et al., who noted a change in central and peripheral P1 latency of 6 ms with vitamin A 4 
supplementation in a single participant case study [35]. For mfERG latency the sample sizes used in 5 
this study gave a power of 80% at the 5% significance level.  6 
 7 
Inclusion criteria 8 
Suitability for inclusion was evaluated by questionnaire, fundus photographs and VA. For inclusion 9 
participants had to provide written informed consent and were required to have best corrected VA of at 10 
least 0.2 LogMAR (for good mfERG central fixation), clear optical media, no signs of retinal or optic 11 
nerve disease, good general health and not taking medication that affects the retina.  12 
 13 
Exclusion criteria 14 
Moderate to dense lens opacities, intraocular lens implants, corneal opacities, glaucoma or ocular 15 
hypertension, history of intraocular inflammation, retinal detachment or retinal disease, retinal laser, 16 
diabetes, alcoholism, systemic hypertension, epilepsy, ocular surgery (excluding LASIK/EK), ocular 17 
trauma or neurological disease in the studied eye. Participants with a history of taking medications that 18 
cause retinal toxicity (e.g. topiramate, metronidazole, quinolones, thioridazine, deferoxamine, cisplatin, 19 
oxazepam, vigabatrin, tamoxifen, digoxin) were also excluded. 20 
 21 
Outcome measures 22 
Multifocal Electroretinography  23 
The VERIS science 6.1 (Electrodiagnostic imaging, San Mateo, California, USA) was used to record 24 
the mfERG. The multifocal stimulus, consisting of 61 scaled hexagons was displayed on a high-25 
resolution, black-and-white cathode ray tube monitor 30cm wide and 30 cm high with a frame rate of 26 
75 Hz. The hexagon stimulus radius subtended approximately 20° of visual field. Each hexagon was 27 
independently alternated between white (200 cd/m²) and black (1cd/m²) according to a pseudorandom 28 
binary m-sequence [36]. Total recording time was four minutes. Recording time was divided into eight, 29 
30 second segments allowing for participant rests. Fixation target perception was confirmed before 30 
testing commenced. The fixation target size was 1.5% of the area of the central hexagon. Each subject’s 31 
vision was optimally corrected with the VERIS system’s refractor/camera system. To allow equal 32 
magnification of the stimulus array on the retina, the distance between the participant’s eye and 33 
refractor/camera was adjusted by obtaining a sharp image on the observation monitor as per the 34 
6 
 
manufacturer’s recommendation. The participant’s eye was monitored throughout testing using this 1 
system. Pupils were dilated with tropicamide 1% (Bausch and Lomb, Kingston-Upon-Thames, Surrey, 2 
UK). Gold cup electrodes filled with signa gel (Parker Laboratories, Fairfield, New Jersey, USA) were 3 
applied to the forehead (ground electrode) and approximately 1 cm posterior to the temporal canthus 4 
(reference electrode) of the tested eye after these areas were abraded and cleaned using Nuprep 5 
(Weaver and Company, Aurora, USA). A Dawson Trick Litzkow (DTL) fibre electrode was used as the 6 
active electrode and was placed along the sclera adjacent to the lower eyelid. The participant was asked 7 
to blink to ensure that the electrode found the same natural position for each visit. These electrodes 8 
(Diagnosys UK ltd) were used for the trial for participant comfort [37] and test-retest reliability [38] while 9 
not obscuring vision. Proxymetacaine hydrochloride 0.5% (Bausch and Lomb, Kingston-Upon-Thames, 10 
Surrey, UK) was instilled to minimise blinking throughout the recording. Any recordings contaminated 11 
with artefact were discarded and repeated. The untested eye was obscured throughout the procedure. 12 
In order to remove signal artefacts and improve the signal to noise ratio but without attenuating mfERG 13 
waveforms, one iteration of artefact removal was performed for each mfERG recording. This removed 14 
small eye movement artefacts. No spatial averaging was performed because this would reduce spatial 15 
resolution as each retinal area stimulated by a hexagon is averaged with 1/6th of its neighbouring 16 
hexagons. Thus the waveform of each single retinal area stimulated by a single hexagon would lose 17 
some of its own identity as it was averaged with surrounding waveforms. The mfERG measures were 18 
N1, P1 and N2 latency and N1 P1 amplitude (figure 1) and these were assessed for five rings of retinal 19 
eccentricity (figure 2). 20 
 21 
Insert figures 1 & 2 about here. 22 
 23 
We used a 61 hexagon stimulus as recommended by ISCEV mfERG guidelines to balance the 24 
necessity for participant comfort while providing adequate assessment of macular function [39]. This 25 
also replicates the CARMIS study stimulus type [22]. 26 
 27 
Contrast sensitivity 28 
The Pelli-Robson CS test (Clement Clarke International Ltd, Harlow, Essex, UK) was used at 1 m as 29 
per the manufacturer guidelines, with distance refractive correction when required. For consistency CS 30 
was undertaken in the same room for each visit with a background illumination of 142 lux throughout 31 
the trial.  32 
Macular pigment optical density  33 
In order to obtain values for retinal accumulation of L and Z., MPOD was obtained using the Macular 34 
Pigment Screener 9000 (MPS) which uses the principle of heterochromatic flicker photometry (HFP). 35 
7 
 
Participants were required to make flicker matches between two wavelengths of light, a blue light 1 
(~465nm), and green light (~530nm). Flicker matches were initially obtained centrally (1°). Flicker rate 2 
was gradually reduced from above the critical fusion frequency (60 Hz) by 6 Hz until the participant 3 
observed the flicker and pressed a response button accordingly. This procedure continued for a series 4 
of pre-set blue-green ratios. Once flicker was detected the luminance of the blue and green light was 5 
changed by 0.2dB increasing the blue light and decreasing the green light while the overall mean 6 
luminance was kept constant. Then the temporal frequency was reset to 60 Hz and the frequency 7 
reduced by 6 Hz again. The sequence continued for a series of blue-green ratios until a V-shaped curve 8 
was obtained. The minimum value of this curve was where the blue and green lights were of equal 9 
luminance. This whole process was repeated peripherally (8°) and again a V-shaped curve was 10 
obtained, providing a minimum value where blue a green lights were equiluminant. Because MP 11 
selectively absorbs blue light and is found centrally but not peripherally, the central minimum value 12 
differed from the peripheral minimum value. Macular Pigment Optical Density was determined by 13 
dividing central minimum blue light intensity by peripheral minimum blue light intensity and log10 of this 14 
value using MPS computer software. Greater detail of this technique is described by Van Der Veen et 15 
al. [40]. The background and target luminance was set to 250 cd/m². Participants wore distance glasses 16 
for the test if required, and were instructed to fixate on the central target for obtaining central values. 17 
For peripheral testing participants were asked to blink frequently and adopt a more relaxed fixation at 18 
8° around a 1.75° red fixation target to reduce Troxler’s effect.  19 
Visual acuity 20 
LogMAR distance VA testing using a 3 m ETDRS 750 lux retro-illuminated chart was undertaken for 21 
each participant (Sussex vision, Rustington, West Sussex, UK). The eye with the best corrected VA 22 
was determined at the participant’s first visit and this eye was assessed for the subsequent visits.  23 
Intraocular pressure 24 
Non-contact intraocular pressure readings (Topcon CT-80 non-contact tonometer, Topcon, Newbury, 25 
Berkshire, UK) were taken prior to instillation of tropicamide 1%.  26 
Fundus photography 27 
A central 45° fundal photograph was taken with the Topcon TRC-NW8, (Topcon, Newbury, Berkshire, 28 
UK) at each visit to determine any change in fundus or media opacity. Participants were instructed to 29 
fixate on a central fixation target for each visit to ensure identical fundus positioning. Any changes in 30 
fundus or media opacity would have resulted in exclusion from the study.  31 
 32 
Food Diaries 33 
In order to assess whether any changes in outcome measures were due to the L-based nutritional 34 
supplement rather than changes in dietary intake of nutrients, each participant was provided with a 35 
8 
 
food diary. The diary was filled in over two week days and one weekend day. Participants were given 1 
food diaries at visits one and three. The data from the food diaries was analysed using the Weighted 2 
Intake Software Package (WISP, Tinuviel, Llanfechell, Anglesey, UK). Lutein values for foods were 3 
taken from the United States Department of Agriculture (USDA) nutrient databank, release 23 4 
(http://www.ars.usda.gov/SP2UserFiles/Place/12354500/Data/SR23/nutrlist/sr23a338.pdf). 5 
 6 
Results 7 
There were 25 participants (mean age ± SD; 48.68 ± 17.35, range 18-77 years) in the treated group 8 
and 27 (mean age ± SD; 43.93 ± 16.15, range 21-69 years) in the non-treated group. All participants in 9 
the treated group were Caucasian, consisting of 15 females and 10 males. In the non-treated group 10 
there were 20 females and 7 males, 5 South Asians and 22 White. A chi-squared test for independence 11 
demonstrated a significant difference between treated and non-treated groups for ethnicity (Χ2 = 5.122, 12 
p = 0.024) but not for gender (Χ2 = 1.169, p = 0.280). There was no significant difference between 13 
treated and non-treated groups for VA, CS or MPOD.  14 
Due to technical difficulties mfERG parameters were not measured for all participants for each visit. 15 
Only 25 participants (15 in the treated group and 10 in the non-treated group) underwent mfERG for all 16 
three visits. However the VA, CS and MPOD were undertaken on all 52 participants. A summary of 17 
differences in baseline characteristics are detailed in table 3 and were analysed using independent-18 
samples t-tests. Of the 25 participants in the treated group 14 participants returned their baseline dietary 19 
questionnaire (56.0%). Of the 27 participants in the non-treated group 17 returned their baseline dietary 20 
questionnaire (63.0%) 21 
 22 
Insert table 3 about here. 23 
 24 
Each data set was checked for normality using the Shapiro-Wilk statistic which assesses the normality 25 
of distribution of the data. A non-significant result indicates normality and therefore ANOVA was used 26 
for analysis with Tukey’s post-hoc range test. When parametric assumptions were not met according 27 
to Shapiro-Wilk tests for normality Kruskal-Wallis one-way analysis of variance for independent groups 28 
was performed with Mann-Whitney U tests demonstrating post-hoc differences between groups. 29 
In addition, a mixed between-within subjects ANOVA using SPSS 16.0 software (IBM, North Harbour, 30 
Portsmouth, UK) was conducted to explore  the effects of nutritional supplementation compared with 31 
no treatment on retinal function over three time periods using mfERG amplitudes and latencies for 32 
different areas of retinal eccentricity. This provided analysis of the between-subjects variable (treated 33 
and non-treated group), and within-subject variable (time) on the outcome measures (dependent 34 
variable). This test is considered to be tolerant of data distributions that vary from normal  [41]. Post-35 
9 
 
hoc testing was used in lieu of a Bonferroni correction. The significant ANOVA results for mfERG are 1 
displayed in table 4. 2 
 3 
Insert table 4 about here. 4 
 5 
For all mfERG outcome measures there was no significant interaction between treated and non-treated 6 
groups over three time periods or for group (treated versus non-treated) for any mfERG parameters. 7 
There was no significant effect for time for any mfERG parameter except for ring 2 P1 and ring 2 N2 8 
latency (see table 5a). Ring 2 N2 latency became longer over the three visits for both groups. Ring 2 9 
P1 latency became statistically significantly shorter over three visits in the treated group (see table 5b), 10 
although this change was not clinically significant based coefficient of repeatability (CR) values obtained 11 
within our laboratory. 12 
 13 
Insert table 5a about here 14 
Insert table 5b about here. 15 
 16 
All participants (25 in the treated group and 27 in the non-treated groups) undertook VA and CS 17 
measurements at all three visits. One participant in the treated group was unable to perform the MPOD 18 
at one of their visits (therefore n=24 for the treated group and n=27 in the non-treated group for this 19 
test). There was no statistically significant difference between treated and non-treated eyes for VA or 20 
CS. There was a significant interaction effect between time and group for MPOD, with MPOD increasing 21 
over the three visits by 0.1 in the treated group compared with a 0.03 reduction in MPOD in the non-22 
treated group between visits one and three (F = 17.00, p < 0.001).  23 
 24 
Insert table 6 about here. 25 
Insert figure 3 about here. 26 
 27 
Of the 14 people in the treated group who completed the baseline dietary questionnaire, eight 28 
completed a further questionnaire at visit three. Of the 17 people in the non-treated group who 29 
completed the baseline dietary questionnaire, 10 completed a further questionnaire at visit three. A 30 
paired-samples t-test using SPSS 16.0 demonstrated no significant difference for any of the dietary 31 
components between visits one and three in the treated group and the non-treated group (p > 0.05). 32 
10 
 
Compliance was assessed by asking participants to return any boxes of the supplement that were not 1 
taken and remaining tablets were counted. Those who forgot to bring back the tablets were asked to 2 
contact the principle investigator after counting tablets at home. Patient compliance was elicited using 3 
supportive language to minimise the number of participants concealing supplement non-adherence 4 
[42], and reporting lower levels of remaining tablets than was actually the case. The sole reason for 5 
non-adherence was forgetfulness. A one way ANOVA using SPSS 16.0 found no statistically significant 6 
difference between groups for supplement compliance during the study (see table 7) (F = 0.40, p = 7 
0.68). 8 
 9 
Insert table 7 about here 10 
 11 
Discussion 12 
This randomised controlled trial was designed to assess the effect of a nutritional supplement containing 13 
12 mg L, 0.6 mg Z, 150 mg vitamin C, 15 mg of vitamin E, 400 µg copper, 20 mg zinc and 1080 mg 14 
omega-3 fatty acids on objective and subjective clinical measures of visual and retinal function in 15 
healthy eyes. 16 
There was a statistically significant increase in MPOD and shortening of ring 2 P1 latency, with 17 
supplementation. It is important to also consider the clinical significance of these findings. Clinical 18 
significance is related to the reliability of the instrumentation being used. The reliability is quantified 19 
using the coefficient of repeatability and was calculated for each outcome measure within our 20 
laboratory. If the change in outcome recorded is less that the coefficient of repeatability, then it is not 21 
possible to conclude that the change is not simply due to measurement noise. Although neither of these 22 
statistically significant changes can be considered clinically significant based on coefficient of 23 
repeatability data from our laboratory, the trends demonstrated may warrant further investigation.  24 
Many studies have demonstrated an increase in MPOD with L-based supplementation in healthy eyes 25 
[9-11,43,12-17]. However not all studies have assessed whether this increased retinal accumulation of 26 
MP is associated with changes to other measures of visual and retinal function such as CS, VA or 27 
mfERG [11,10,43,13-15,17]. Some studies also failed to report dietary levels of L and Z during 28 
supplementation [10,11,13-16].  29 
There have been conflicting results within the literature with regards to the effects of nutritional 30 
supplementation on visual function in healthy eyes. A study by Sasamoto et al. assessing the effects of 31 
a nutritional supplement on MPOD and visual function showed that MPOD did not significantly increase 32 
over 12 months, although improvements in CS were seen [44]. It is difficult to compare this with the 33 
current study as different methods of assessing MPOD (autofluorescence spectrometry) and CS (area 34 
under the log contrast sensitivity function) were used, and supplement formulation (6mg L), ethnicity 35 
11 
 
(Japanese) and study design were not the same. Also some of the participants in Sasamoto et al’s 1 
study consisted of healthy fellow eyes of those with AMD or central serous chorioretinopathy which may 2 
have been subject to subtle retinal changes not clinically visible.  3 
The Collaborative Optical Macular Pigment Assessment Study (COMPASS) investigators concluded 4 
that supplementing with 12 mg of L, 1 mg of Z and antioxidants in healthy eyes significantly increased 5 
MPOD over 12 months, but this did not correspond with an improvement in VA or photopic CS [45]. 6 
This is in agreement with our study but a different method of CS assessment was used (contrast 7 
sensitivity function), the sample size was larger at 121 subjects and the supplement formulation differed.  8 
A 12 week study of 37 healthy eyes found no statistically significant improvement in VA or central CS 9 
when supplementing with 6 or 12 mg of L [46]. Improvements were noted at wider fields of CS analysis. 10 
This study differed from the current one in supplement formulation, ethnicity (Chinese) and methods of 11 
CS (automated contrast glare tester) assessment.  12 
A study by Bartlett and Eperjesi concluded that supplementing with 6 mg of L combined with vitamins 13 
and minerals did not improve CS or VA over 9 or 18 months [47]. The same methods of VA and CS 14 
assessment were used, and a similar study design as the current study although supplement 15 
formulation differed.  16 
To the authors’ knowledge, the literature provides no information with regards to the effects of nutritional 17 
supplementation on mfERG measures in healthy eyes. Ring 2 P1 latency of the mfERG became 18 
statistically significantly shorter over time in those taking the supplement. Although there was a 19 
difference between treated and non-treated groups for ethnicity for the current study there is no reason 20 
to believe that the results would have been different if the treated group had contained similar numbers 21 
of Asians as the non-treated group.  22 
The CARMIS investigators found that a 10 mg L-based supplement over 12 months increased N1P1 23 
amplitudes in rings 1 and 2 of the mfERG in 15 eyes with ARM or non-central geographic atrophy [22]. 24 
We did not find any mfERG amplitude increase in our healthy supplemented eyes, although the 25 
supplement composition was not the same as the CARMIS supplement formula. Unlike the current 26 
study, the CARMIS investigators did not report dietary levels of L and Z throughout the study period, 27 
thus it is difficult to determine if the mfERG changes seen were due supplementary or dietary changes 28 
in L and Z. Retinal accumulation of L and Z (MPOD) was not measured in the CARMIS study, thus it is 29 
impossible to ascertain if increased retinal levels of L and Z were related to the increased central mfERG 30 
amplitudes reported in their study. 31 
The study formulation also contained omega-3 essential fatty acids, which may also be implicated in 32 
the statistically significant change in Ring 2 P1 latency. Observational studies support the hypothesis 33 
that omega 3 poly-unsaturated fatty acids (PUFA) are protective in the eye. A 2008 meta-analysis of 34 
epidemiological studies reported that a high intake of omega-3 fatty acids and fish intake at least twice 35 
a week may reduce the primary risk of early and late AMD by up to 38%. [48].  In a 5-year follow-up 36 
study of the Blue Mountains Eye Study cohort, fish consumption at least once a week was associated 37 
12 
 
with a 40% reduction in incident early age-related macular degeneration, and more frequent 1 
consumption of fish (3 times a week) was found to be protective against late ARM. [49]. Other studies 2 
have found similar findings. [24], [25] [26], [16]. Some prospective studies also reveal a decreased 3 
likeliness of AMD progression in those with early AMD. [7, 17, 18]. 4 
 5 
Study limitations 6 
The age range of participants (18-77 years) may have implications for the interpretation of results, as it 7 
has been demonstrated that mfERG parameters are correlated with age [50,51]. In addition, the use of 8 
ring averages to estimate effects may have resulted in underestimation of the true magnitude of effect 9 
due to age effect variability between individual rings [52].  10 
Food diaries were prospective and were completed over several days in order to provide detailed dietary 11 
information. Return rates were low. A recall food diary may have provided a greater number of returned 12 
questionnaires as participants could have completed these during their visits. However, this may not 13 
have been as accurate due to participants having to remember their food intake over a three day period. 14 
Serum analysis would have provided a more accurate overview of compliance and dietary habits. It 15 
would have been useful to record body mass index (BMI) for all participants, as a BMI greater than 27 16 
has been associated with reduced retinal uptake of Z and so may have confounded the results [53]. 17 
Use of a placebo for the non-treated group would have strengthened the study, but the cost of this was 18 
prohibitive.  19 
Using a combined-nutrient formulation does not allow for any evaluation of the impact of individual 20 
nutrients. It is common, however, to find nutritional supplements that contain a combination of several 21 
nutrients; this is because of the synergistic relationships between them. Examples include copper and 22 
zinc combinations required for copper-zinc superoxide dismutase, a part of the antioxidant system 23 
within the retinal pigment epithelium and retina [54], and increased bioavailability of L with the addition 24 
of certain fats, including olive and peanut oils [55,56]. Use of multi-nutrient formulations in AMD is 25 
supported by the results of the AREDS, in which zinc and antioxidants reduced the relative risk of 26 
developing advanced AMD by 21% and 17% respectively. When zinc and antioxidants were combined, 27 
the risk reduced further to 25% [57].  28 
 29 
Conclusion 30 
The current study adds to literature in several ways. It expands on the CARMIS study by assessing the 31 
effects of an L-based supplement in healthy eyes. The pertinence of this lies in any potential protective 32 
role the supplement may have in delaying onset of AMD in healthy eyes. The assessment of dietary 33 
intake over the study period is important in such studies so as to be able to attribute any changes in 34 
study outcome measures to supplementation rather than diet. Subjective measures of visual function 35 
were undertaken alongside objective measures of retinal function in order to assess whether 36 
13 
 
improvements in retinal function may have been associated with improved subjective measures of 1 
visual function. 2 
The statistically significant accumulation of L and Z within the retina, and improved retinal function in 3 
healthy eyes with L-based supplementation are encouraging. It may be that further beneficial effects of 4 
accumulated MP on retinal and visual function may be witnessed over a longer term and/or with higher 5 
supplement dosage.  6 
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Tables 1 
 2 
Ingredient Safe upper levels per day [33] Dosage 
Vitamin C 1000 mg (guidance only) 150 mg 
Copper 10 mg 400 µg 
Vitamin E 540 mg 15 mg 
Zinc 25 mg 20mg 
Lutein none established 12 mg 
Zeaxanthin none established 0.6 mg 
Omega-3 none established 1080 mg 
Table 1: supplement composition. These amounts were provided by taking two tablets and two capsules 3 
per day.  4 
   5 
20 
 
 1 
 VA 
(logMAR) 
CS 
(log 
units) 
MPOD
 
Central mfERG 
N1P1 amplitude 
(nV/deg2) 
Central mfERG P1 
latency (ms) 
Mean -0.11 1.89 0.39 173.17 29.09 
Standard deviation 
(SD) 
0.11 0.12 0.16 50.12 1.43 
 
Effect size (E) 
 
0.10^^ 
 
0.30^ 
 
0.33* 
 
95.24** 
 
6.00*** 
E/S 0.91 2.50 2.06 1.90 4.20 
(E/SD)2 0.83 6.25 4.25 3.61 17.60 
Sample size = 
16/(E/SD)2 
(two sided) 
19 3 4 4 1 
Table 2: Group sizes required to have 80% power at the 5% significance level for VA, CS, mfERG 2 
amplitude and MPOD for healthy eyes. The mean and standard deviation (SD) data were calculated 3 
from 52 healthy eyes at visit 1. 4 
^^ Based on VA repeatability studies [58-62].  5 
^ Based on Elliot et al’s paper [63]. 6 
* Repeatability value from Bartlett et al’s of HFP repeatability paper [64] 7 
** Based on Parisi et al’s paper of a 55% change in mfERG amplitude [22] 8 
*** Based on Dolan et al’s paper [35] 9 
  10 
21 
 
 1 
Variable Treated group 
(n=25) 
Non-treated group 
(n=27) 
 
 mean ±SD mean ±SD t p 
Age (years) 48.68 17.35 43.93 16.15 1.02 0.31 
Smoking (pack-years)* 2.02 3.32 2.73 6.08 -0.52 0.61 
Spherical equivalent (D) 0.64 2.21 0.22 2.24 0.68 0.50 
Axial length (mm) 23.31 1.12 23.68 1.07 -1.23 0.23 
Baseline dietary 
questionnaires 
Treated group 
(n=14) 
Non-treated group 
(n=17) 
 
 mean ±SD mean ±SD t p 
Dietary copper (mg) 1.37 0.87 1.00 0.38 1.60 0.12 
Dietary zinc (mg) 7.40 2.08 6.84 1.91 0.78 0.44 
Dietary retinol (µg) 705.57 1584.91 207.12 122.74 1.17 0.26 
Dietary carotene (µg) 1789.71 1216.07 2557.59 2272.45 -1.20 0.24 
Dietary Vitamin E (mg) 3.67 1.25 5.09 2.26 -1.45 0.17 
Dietary Vitamin C (mg) 85.43 64.73 102.59 60.16 -0.76 0.45 
Dietary lutein and 
zeaxanthin (µg) 
1295.33 924.07 2016.29 2044.30 -1.30 0.21 
Dietary Omega 3 (g) 0.17 0.12 0.15 0.15 0.30 0.76 
Table 3: A summary of baseline characteristics for treated and non-treated healthy eyes using 2 
independent-samples t-tests. 3 
  4 
22 
 
Outcome measure Main effect: time Main effect: group 
(treated/non-treated) 
Interaction effect 
 F p F p F p 
Ring 2 P1 latency 5.067 0.015 0.188 0.668 3.694 0.041 
Ring 2 N2 latency 3.622 0.044 0.191 0.666 0.095 0.910 
Table 4: Significant results (shaded) from a mixed between-within ANOVA for mfERG N1P1 1 
amplitude, N1 latency, P1 latency and N2 latency over three visits for five areas of retinal eccentricity 2 
between treated and non-treated healthy eyes. The shaded areas indicate statistical significance. 3 
  4 
23 
 
 1 
Outcome measure Main effect: time Main effect: group 
(treated/non-treated) 
Interaction effect 
 F p F p F p 
Ring 1 N1-P1 amplitude 0.311 0.736 0.617 0.440 0.067 0.935 
Ring 2 N1-P1 amplitude 1.642 0.216 0.058 0.812 0.034 0.966 
Ring 3 N1-P1 amplitude 1.659 0.213 0.112 0.741 0.063 0.939 
Ring 4 N1-P1 amplitude 1.408 0.266 0.212 0.650 0.068 0.934 
Ring 5 N1-P1 amplitude 0.007 0.993 1.894 0.182 0.193 0.826 
Ring 1 N1 latency 1.203 0.319 1.072 0.311 0.957 0.400 
Ring 2 N1 latency 0.579 0.569 1.868 0.185 0.253 0.778 
Ring 3 N1latency 0.196 0.823 0.280 0.602 0.513 0.606 
Ring 4 N1 latency 0.695 0.510 <0.001 0.998 0.101 0.905 
Ring 5 N1 latency 0.481 0.624 0.057 0.813 0.543 0.588 
Ring 1 P1 latency 3.172 0.062 1.973 0.174 1.294 0.294 
Ring 2 P1 latency 5.067 0.015 0.188 0.668 3.694 0.041 
Ring 3 P1 latency 1.401 0.268 0.365 0.552 0.118 0.889 
Ring 4 P1 latency 1.046 0.368 0.011 0.917 0.081 0.923 
Ring 5 P1 latency 1.495 0.246 1.430 0.244 1.319 0.288 
Ring 1 N2 latency 2.761 0.085 0.216 0.646 0.869 0.433 
Ring 2 N2 latency 3.622 0.044 0.191 0.666 0.095 0.910 
Ring 3 N2 latency 3.053 0.068 <0.001 0.999 1.042 0.369 
Ring 4 N2 latency 1.700 0.206 1.517 0.230 0.607 0.554 
Ring 5 N2latency 1.490 0.247 0.057 0.814 0.509 0.608 
Table 5a: Mixed between-within ANOVA for mfERG N1P1 amplitude, N1 latency, P1 latency and N2 2 
latency over 3 visits for 5 areas of retinal eccentricity between treated and non-treated groups for 3 
combined HY and HO eyes. The shaded areas indicate statistical significance. 4 
   5 
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 1 
  Visit 1 Visit 2 Visit 3 
  Mean ± SD Mean ± SD Mean ± SD 
R2 P1 latency Treated (n=15) 28.56 ± 1.46 28.50 ± 1.48 27.89 ± 1.83 
(ms) Non-treated 
(n=10) 
28.25 ± 1.38 29.08 ± 1.33 28.33 ±1.24 
R2 N2 latency Treated (n=15) 42.33 ± 1.84 43.06 ± 1.85 43.28 ± 1.65 
(ms) Non-treated 
(n=10) 
42.58 ± 1.73 43.42 ± 1.21 43.42 ± 1.33 
Table 5b: Mean values ± SD for significantly changed mfERG measures between treated and non-2 
treated healthy eyes over three visits. 3 
 4 
 Visit 1 Visit 2 Visit 3 
 Mean ± SD Mean ± SD Mean ± SD 
VA (logMAR units) 
Treated -0.09 ± 0.09 -0.07 ± 0.08 -0.10 ± 0.09 
Non-treated -0.12 ± 0.12 -0.06 ± 0.08 -0.10 ± 0.09 
CS (log units) 
Treated 1.88 ± 0.13 1.88 ± 0.13 1.89 ± 0.12 
Non-treated 1.89 ± 0.12 1.89 ± 0.12 1.92 ± 0.10 
MPOD (optical density units) 
Treated 0.35 ± 0.16 0.40 ± 0.14 0.45 ±0.12 
Non-treated 0.42 ± 0.16 0.42 ± 0.16 0.39 ± 0.16 
Table 6: Mean values ± SD between treated and non-treated eyes for VA, CS and MPOD over 3 visits. 5 
The shaded areas indicate statistical significance. 6 
   7 
25 
 
 1 
  Treated Non-treated 
Mean trial duration (months) 
VISIT 
1-2 
5.0 ± 0.9 4.9 ± 0.7 
VISIT 
1-3 
10.6 ± 1.2 10.6 ± 1.4 
Mean compliance (% tablets taken)  79.5 ± 15.9 N/A 
Table 7: Summary of trial duration (mean ± SD) and participant compliance (% ± SD). 2 
 3 
Figure legends 4 
Figure 1: A normal mfERG response. The double ended arrow demonstrates N1P1 amplitude (source 5 
- authors own drawing). 6 
Figure 2: Grouping of the mfERG areas analysed. Ring 1- red hexagon, ring 2 - beige hexagons, ring 7 
3 - green hexagons, ring 4 - pink hexagons, ring  5 - blue hexagons. 8 
Figure 3: Differences between mean MPOD values over three visits between treated and non-treated 9 
groups for healthy eyes. 10 
